Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 52,000 KRW
Change Today -6,700.00 / -11.41%
Volume 835.1K
As of 2:29 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

seegene inc (096530) Snapshot

Open
58,700
Previous Close
58,700
Day High
59,400
Day Low
52,000
52 Week High
07/22/15 - 71,700
52 Week Low
12/22/14 - 29,350
Market Cap
1.4T
Average Volume 10 Days
1.0M
EPS TTM
355.33
Shares Outstanding
26.2M
EX-Date
--
P/E TM
146.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for SEEGENE INC (096530)

Related News

No related news articles were found.

seegene inc (096530) Related Businessweek News

No Related Businessweek News Found

seegene inc (096530) Details

Seegene, Inc. develops molecular diagnostics systems for various applications. It offers IVD reagets comprising respiratory pathogens for the detection of respiratory viruses and bacteria, pneumonia bacteria, and influenza A and influenza B virus; sexually transmitted infections causative pathogens detection product; human papillomavirus detection products; tuberculosis detection products; Magicplex sepsis real-time test screens; meningitis pathogens for the detection of viruses and bacteria causing human meningitis; and diarrhea pathogens for the detection of viruses and bacteria causing diarrhea. The company also provides Anyplex and Seeplex products for the detection of vanA, vanB, and vanC genes; two mutations causing clarithromycin-resistance; Apolipoprotein E genotypes from blood samples; hepatitis A, B and C virus; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, FNAB, H&E slides, and paraffin-embedded tissues; BCR/ABL fusion gene from blood and whole bone marrow; and CMV infection from whole blood and plasma. In addition, it offers automatic real time detection systems; liquid handling workstations and automated magnetic bead based nucleic acid extractions systems; PCR machines; LabChip, a nucleic acid separations system; and MultiNA, a microchip electrophoresis system. Seegene, Inc. has operations in Asia, Oceania, the Middle East, Africa, the United States, and South Korea, as well as central, northern, eastern, and west Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Founded in 2000

seegene inc (096530) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seegene inc (096530) Key Developments

Seegene and Qiagen Enter into Collaboration to Develop Molecular Diagnostic Assays

Seegene has signed an agreement with Qiagen to develop and supply molecular diagnostic assays. Under the agreement, Seegene will develop and manufacture multiplex infectious disease testing panels designed for Qiagen's proprietary real-time PCR cycler Rotor-Gene Q product, and Qiagen will gain global commercialization rights to these tests.

Seegene Inc. to Develop Menu of Multiplex Assay Panels for Qiagen N.V

QIAGEN N.V. announced a collaboration in which Seegene Inc. will develop a menu of multiplex assay panels for its modular QIAsymphony RGQ MDx automation platform. The first project is to develop comprehensive panels to profile infectious diseases. Seegene's proprietary technologies for multiplexed real-time PCR analysis enable simultaneous amplification of up to 20 target genes per tube in a single reaction. QIAGEN will validate the new tests to run on QIAsymphony RGQ MDx, its automation solution, and will market them worldwide as QIAGEN-branded assays, beginning in Europe and Asia. QIAsymphony is an innovative, easy-to-use modular system that integrates a molecular laboratory's workflow from initial biological sample processing to final insights. The three modules of QIAsymphony RGQ MDx are QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup (integrated into the SP module), and QIAGEN's real-time PCR detection platform Rotor-Gene Q MDx. QIAsymphony RGQ MDx received FDA clearance in early 2014. The menu of diagnostics running on the QIAsymphony platform so far includes 13 CE-IVD marked tests available in 30 European countries and six FDA-approved or cleared diagnostics in the United States. QIAGEN's first highly multiplexed assay running on Rotor-Gene Q, the RespiFinder RG Panel for detection and differentiation of 21 respiratory pathogens, was recently launched in Europe.

Seegene, Inc., Annual General Meeting, Mar 27, 2015

Seegene, Inc., Annual General Meeting, Mar 27, 2015., at 09:00 Korea Standard Time. Location: Taiyuan 65-5 Building (main) Seegene B1 AuditoriumBangi-dong. Agenda: To consider audit report; to consider business report for 15th period ended December 31, 2014; to consider appointment of directors; and to approve director remuneration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
096530:KS 52,000.00 KRW -6,700.00

096530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $54.95 USD -0.64
GenMark Diagnostics Inc $8.00 USD -0.50
Luminex Corp $17.12 USD -0.11
QIAGEN NV €25.71 EUR +0.319
Sequenom Inc $2.69 USD -0.13
View Industry Companies
 

Industry Analysis

096530

Industry Average

Valuation 096530 Industry Range
Price/Earnings 100.0x
Price/Sales 22.0x
Price/Book 14.6x
Price/Cash Flow 113.8x
TEV/Sales 21.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEEGENE INC, please visit www.seegene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.